Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment Definitions
1.2. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.4.6. Research Assumption
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Data Visualization
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. Objectives
1.8.1. Objective - 1
1.8.2. Objective - 2
1.8.3. Objective - 3
1.9. List of Secondary Sources
1.10. List of Secondary Sources
Chapter 2. Executive Summary
2.1. U.S. Peptide Therapeutics (Retail Side) Market
2.1.1. Market Snapshot
2.1.2. Segment Snapshot
2.1.2.1. Therapeutics type & indication segment outlook
2.1.2.2. Route of administration & distribution channel segment outlook
2.1.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.2. Market Restraint Analysis
3.4. Regulatory Framework
3.5. Business Environment Analysis Tools
3.5.1. Industry Analysis - Porter’s Five Forces Analysis
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.6. Pricing Analysis in Online vs. Offline Channels
3.7. Consumer Awareness Trends for Peptide Therapies
3.8. Direct-to-Consumer (DTC) Business Models Impact
Chapter 4. Peptide Type Business Analysis
4.1. U.S. Peptide Therapeutics (Retail Side) Market: Peptide Type Movement Analysis
4.2. U.S. Peptide Therapeutics (Retail Side) Market: Peptide Type Segment Dashboard
4.3. Peptide Type Movement & Market Share Analysis, 2024 & 2033
4.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Peptide Type
4.5. GLP-1 Peptides
4.5.1. GLP-1 Peptides Market, 2021-2033 (USD Million)
4.6. Wellness/Longevity/Healthspan Peptides
4.6.1. Wellness/Longevity/Healthspan Peptides Market, 2021-2033 (USD Million)
4.7. Peptides for Other Acute or Chronic Medical Conditions
4.7.1. Peptides for Other Acute or Chronic Medical Conditions Market, 2021-2033 (USD Million)
Chapter 5. Therapeutics Type Business Analysis
5.1. U.S. Peptide Therapeutics (Retail Side) Market: Therapeutics Type Movement Analysis
5.2. U.S. Peptide Therapeutics (Retail Side) Market: Therapeutics Type Segment Dashboard
5.3. Therapeutics Type Movement & Market Share Analysis, 2024 & 2033
5.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Therapeutics Type
5.5. Innovative (Branded) Peptides
5.5.1. Innovative (Branded) Peptides Market, 2021-2033 (USD Million)
5.6. Biosimilar Peptides
5.6.1. Biosimilar Peptides Market, 2021-2033 (USD Million)
5.7. Generic Peptides
5.7.1. Generic Peptides Market, 2021-2033 (USD Million)
Chapter 6. Indication Business Analysis
6.1. U.S. Peptide Therapeutics (Retail Side) Market: Indication Movement Analysis
6.2. U.S. Peptide Therapeutics (Retail Side) Market: Indication Segment Dashboard
6.3. Indication Movement & Market Share Analysis, 2024 & 2033
6.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Indication
6.5. Type 2 Diabetes
6.5.1. Type 2 Diabetes Market, 2021-2033 (USD Million)
6.6. Obesity / Weight Management
6.6.1. Obesity / Weight Management Market, 2021-2033 (USD Million)
6.7. Neuroendocrine Tumors
6.7.1. Neuroendocrine Tumors Market, 2021-2033 (USD Million)
6.8. Acromegaly
6.8.1. Acromegaly Market, 2021-2033 (USD Million)
6.9. Growth Hormone Deficiency
6.9.1. Growth Hormone Deficiency Market, 2021-2033 (USD Million)
6.10. Prostate Cancer
6.10.1. Prostate Cancer Market, 2021-2033 (USD Million)
6.11. Osteoporosis
6.11.1. Osteoporosis Market, 2021-2033 (USD Million)
6.12. Breast Cancer (hormone-sensitive)
6.12.1. Breast Cancer (hormone-sensitive) Market, 2021-2033 (USD Million)
6.13. Endometriosis
6.13.1. Endometriosis Market, 2021-2033 (USD Million)
6.14. Others
6.14.1. Others Market, 2021-2033 (USD Million)
Chapter 7. Route of Administration Business Analysis
7.1. U.S. Peptide Therapeutics (Retail Side) Market: Route of Administration Movement Analysis
7.2. U.S. Peptide Therapeutics (Retail Side) Market: Route of Administration Segment Dashboard
7.3. Route of Administration Movement & Market Share Analysis, 2024 & 2033
7.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Route of Administration
7.5. Oral
7.5.1. Oral Market, 2021-2033 (USD Million)
7.6. Parenteral
7.6.1. Parenteral Market, 2021-2033 (USD Million)
7.7. Transdermal
7.7.1. Transdermal Market, 2021-2033 (USD Million)
7.8. Nasal
7.8.1. Nasal Market, 2021-2033 (USD Million)
7.9. Other Route of Administration
7.9.1. Other Route of Administration Market, 2021-2033 (USD Million)
Chapter 8. Distribution Channel Business Analysis
8.1. U.S. Peptide Therapeutics (Retail Side) Market: Distribution Channel Movement Analysis
8.2. U.S. Peptide Therapeutics (Retail Side) Market: Distribution Channel Segment Dashboard
8.3. Distribution Channel Movement & Market Share Analysis, 2024 & 2033
8.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Distribution Channel
8.5. Offline Retail Pharmacies
8.5.1. Offline Retail Pharmacies Market, 2021-2033 (USD Million)
8.5.2. Chain Pharmacies
8.5.2.1. Chain Pharmacies Market, 2021-2033 (USD Million)
8.5.3. Specialty Retail Pharmacies
8.5.3.1. Specialty Retail Pharmacies market, 2021-2033 (USD Million)
8.5.4. Independent Community Pharmacies
8.5.4.1. Specialty Market, 2021-2033 (USD Million)
8.6. Online Pharmacies / Telehealth
8.6.1. Online Pharmacies / Telehealth Market, 2021-2033 (USD Million)
8.7. Others (Specialized Peptide Clinics)
8.7.1. Others (Specialized Peptide Clinics) Market, 2021-2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Categorization (Offline Pharmacies)
9.2. Company Categorization (Online Pharmacies)
9.3. Company Categorization (Specialized Hormone Clinics)
9.4. Participant’s Overview
9.4.1. Offline Pharmacies
9.4.2. Online Pharmacies
9.4.3. Specialized Hormone Clinics
9.5. Company Market Position Analysis
9.6. Strategy Mapping
9.6.1. Regional Expansion
9.6.2. Mergers & Acquisitions
9.6.3. Others
9.7. Company Profiles/Listing
9.8. Offline Pharmacies
9.8.1. CVS Health
9.8.1.1. Overview
9.8.1.2. Financial performance
9.8.1.3. Product benchmarking
9.8.1.4. Strategic initiatives
9.8.2. Walgreens Boots Alliance, Inc.
9.8.2.1. Overview
9.8.2.2. Financial performance
9.8.2.3. Product benchmarking
9.8.2.4. Strategic initiatives
9.8.3. Walmart Pharmacy
9.8.3.1. Overview
9.8.3.2. Financial performance
9.8.3.3. Product benchmarking
9.8.3.4. Strategic initiatives
9.8.4. Rite Aid Corp
9.8.4.1. Overview
9.8.4.2. Financial performance
9.8.4.3. Product benchmarking
9.8.4.4. Strategic initiatives
9.8.5. The Kroger Co.
9.8.5.1. Overview
9.8.5.2. Financial performance
9.8.5.3. Product benchmarking
9.8.5.4. Strategic initiatives
9.8.6. Albertsons
9.8.6.1. Overview
9.8.6.2. Financial performance
9.8.6.3. Product benchmarking
9.8.6.4. Strategic initiatives
9.8.7. Publix
9.8.7.1. Overview
9.8.7.2. Financial performance
9.8.7.3. Product benchmarking
9.8.7.4. Strategic initiatives
9.8.8. Costco Wholesale Corporation
9.8.8.1. Overview
9.8.8.2. Financial performance
9.8.8.3. Product benchmarking
9.8.8.4. Strategic initiatives
9.8.9. Meijer, Inc.
9.8.9.1. Overview
9.8.9.2. Financial performance
9.8.9.3. Product benchmarking
9.8.9.4. Strategic initiatives
9.9. Online Pharmacies
9.9.1. Hims & Hers Health, Inc
9.9.1.1. Overview
9.9.1.2. Financial performance
9.9.1.3. Product benchmarking
9.9.1.4. Strategic initiatives
9.9.2. Ro (Roman Health Ventures Inc.)
9.9.2.1. Overview
9.9.2.2. Financial performance
9.9.2.3. Product benchmarking
9.9.2.4. Strategic initiatives
9.9.3. Lemonaid Health, Inc.
9.9.3.1. Overview
9.9.3.2. Financial performance
9.9.3.3. Product benchmarking
9.9.3.4. Strategic initiatives
9.9.4. Mark Cuban Cost Plus Drug Company, PBC
9.9.4.1. Overview
9.9.4.2. Financial performance
9.9.4.3. Product benchmarking
9.9.4.4. Strategic initiatives
9.9.5. Amazon.com, Inc.
9.9.5.1. Overview
9.9.5.2. Financial performance
9.9.5.3. Product benchmarking
9.9.5.4. Strategic initiatives
9.9.6. Blink Health Administration LLC, Inc.
9.9.6.1. Overview
9.9.6.2. Financial performance
9.9.6.3. Product benchmarking
9.9.6.4. Strategic initiatives
9.9.7. GoodRx, Inc
9.9.7.1. Overview
9.9.7.2. Financial performance
9.9.7.3. Product benchmarking
9.9.7.4. Strategic initiatives
9.9.8. Honeybee Health Inc.
9.9.8.1. Overview
9.9.8.2. Financial performance
9.9.8.3. Product benchmarking
9.9.8.4. Strategic initiatives
9.9.9. TruePill (acquired by LetsGetChecked in October 2024)
9.9.9.1. Overview
9.9.9.2. Financial performance
9.9.9.3. Product benchmarking
9.9.9.4. Strategic initiatives
9.9.10. AgelessRx
9.9.10.1. Overview
9.9.10.2. Financial performance
9.9.10.3. Product benchmarking
9.9.10.4. Strategic initiatives
9.10. Specialized Hormone Clinics
9.10.1. Defy Medical
9.10.1.1. Overview
9.10.1.2. Financial performance
9.10.1.3. Product benchmarking
9.10.1.4. Strategic initiatives
9.10.2. Renew Vitality
9.10.2.1. Overview
9.10.2.2. Financial performance
9.10.2.3. Product benchmarking
9.10.2.4. Strategic initiatives
9.10.3. Victory Men’s Health
9.10.3.1. Overview
9.10.3.2. Financial performance
9.10.3.3. Product benchmarking
9.10.3.4. Strategic initiatives
9.10.4. Hone Health
9.10.4.1. Overview
9.10.4.2. Financial performance
9.10.4.3. Product benchmarking
9.10.4.4. Strategic initiatives
9.10.5. Joi & Blokes
9.10.5.1. Overview
9.10.5.2. Financial performance
9.10.5.3. Product benchmarking
9.10.5.4. Strategic initiatives
9.10.6. Ways2Well
9.10.6.1. Overview
9.10.6.2. Financial performance
9.10.6.3. Product benchmarking
9.10.6.4. Strategic initiatives
9.10.7. 4Ever Young Anti-aging Solutions
9.10.7.1. Overview
9.10.7.2. Financial performance
9.10.7.3. Product benchmarking
9.10.7.4. Strategic initiatives
9.10.8. T CLINICS USA
9.10.8.1. Overview
9.10.8.2. Financial performance
9.10.8.3. Product benchmarking
9.10.8.4. Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Market size & forecasts and trend analysis for the therapeutics type segment, 2021-2033 (USD Million)
Table 4 Market size & forecasts and trend analysis for the indication segment, 2021-2033 (USD Million)
Table 5 Market size & forecasts and trend analysis for the route of administration segment, 2021-2033 (USD Million)
Table 6 Market size & forecasts and trend analysis for the distribution channel segment, 2021-2033 (USD Million)
Table 7 Market size & forecasts and trend analysis for the offline retail pharmacies type segment, 2021-2033 (USD Million)
List of Figures
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Indication segment snapshot
Figure 10 Route of administration & therapeutics type segment snapshot
Figure 11 Distribution channel segment snapshot
Figure 12 Competitive landscape
Figure 13 U.S. pharmacy market value, 2024 (USD Billion)
Figure 14 U.S. peptide therapeutics (retail side) market dynamics
Figure 15 U.S. peptide therapeutics (retail side) market: Porter’s five forces analysis
Figure 16 U.S. peptide therapeutics (retail side) market: PESTLE analysis
Figure 17 U.S. peptide therapeutics (retail side) market therapeutics type outlook: Segment dashboard
Figure 18 U.S. peptide therapeutics (retail side) market: Therapeutics type movement & market share analysis, 2024 & 2033
Figure 19 Innovative (branded) peptides market, 2021-2033 (USD Billion)
Figure 20 Generic peptides market, 2021-2033 (USD Billion)
Figure 21 Biosimilar peptides market, 2021-2033 (USD Billion)
Figure 22 U.S. peptide therapeutics (retail side) market indication outlook: Segment dashboard
Figure 23 U.S. peptide therapeutics (retail side) market: Indication movement & market share analysis, 2024 & 2033
Figure 24 Type 2 diabetes market, 2021-2033 (USD Billion)
Figure 25 Obesity/weight management market, 2021-2033 (USD Billion)
Figure 26 Prostate cancer market, 2021-2033 (USD Billion)
Figure 27 Breast cancer (hormone-sensitive) market, 2021-2033 (USD Billion)
Figure 28 Endometriosis market, 2021-2033 (USD Billion)
Figure 29 Growth hormone deficiency market, 2021-2033 (USD Billion)
Figure 30 Acromegaly market, 2021-2033 (USD Billion)
Figure 31 Osteoporosis market, 2021-2033 (USD Billion)
Figure 32 Neuroendocrine tumors market, 2021-2033 (USD Billion)
Figure 33 Others market, 2021-2033 (USD Billion)
Figure 34 U.S. peptide therapeutics (retail side) market route of administration outlook: Segment dashboard
Figure 35 U.S. peptide therapeutics (retail side) market: Route of administration movement & market share analysis, 2024 & 2033
Figure 36 Oral market, 2021-2033 (USD Billion)
Figure 37 Parenteral market, 2021-2033 (USD Billion)
Figure 38 Transdermal market, 2021-2033 (USD Billion)
Figure 39 Nasal market, 2021-2033 (USD Billion)
Figure 40 Others market, 2021-2033 (USD Billion)
Figure 41 U.S. peptide therapeutics (retail side) market distribution channel outlook: Segment dashboard
Figure 42 U.S. peptide therapeutics (retail side) market: Distribution channel movement & market share analysis, 2024 & 2033
Figure 43 Offline retail pharmacies market, 2021-2033 (USD Billion)
Figure 44 Chain pharmacies market, 2021-2033 (USD Billion)
Figure 45 Independent community pharmacies market, 2021-2033 (USD Billion)
Figure 46 Specialty retail pharmacies market, 2021-2033 (USD Billion)
Figure 47 Online pharmacies market, 2021-2033 (USD Billion)
Figure 48 Others (specialized peptide clinics) market, 2021-2033 (USD Billion)
Figure 49 Company categorization (Offline Pharmacies)
Figure 50 Company categorization (Online Pharmacy)
Figure 51 Company categorization (Specialized Clinics)
Figure 52 Company market position analysis
Figure 53 Company market position analysis
Figure 54 Company market position analysis
Figure 55 Strategic framework
